公开(公告)号：US20180193384A1

公开(公告)日：2018-07-12

申请号：US15825275

申请日：2017-11-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Yaki EIDELSTEIN ,  Eran OPHIR ,  Assaf LASK ,  Ran AFIK ,  Noga OR-GEVA ,  Esther BACHAR-LUSTIG

IPC: A61K35/17 ,  A61K39/00 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  C12N5/0783 ,  A61K35/22 ,  A61K35/42 ,  A61K35/407 ,  A61K35/12

CPC classification number: A61K35/17 ,  A61K35/22 ,  A61K35/26 ,  A61K35/28 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N5/0637 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2502/1121

Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

公开(公告)号：US20180169152A1

公开(公告)日：2018-06-21

申请号：US15737290

申请日：2016-06-16

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Chava ROSEN ,  Elias SHEZEN ,  Irit MILMAN KRENTSIS

IPC: A61K35/42 ,  A61K31/675 ,  A61K31/255 ,  A61K9/00 ,  A61K45/06 ,  A61N5/10

Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.

公开(公告)号：US09984183B2

公开(公告)日：2018-05-29

申请号：US15706720

申请日：2017-09-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Tali Kimchi ,  Aharon Weissbrod ,  Genadiy Vasserman

IPC: G08B1/08 ,  G06F17/50 ,  A01K1/03 ,  A01K29/00 ,  G01S3/14 ,  G01S3/786 ,  G06K9/62

CPC classification number: G06F17/5009 ,  A01K1/031 ,  A01K29/005 ,  G01S3/14 ,  G01S3/7864 ,  G06K9/6282

Abstract: A method of identifying and classifying social complex behaviors among a group of model organisms, comprising implanting at least one RFID transponder in each model organism in said group of model organisms; enclosing said group of model organisms in a monitored space divided into RFID monitored segments; RFID tracking a position of each model organism by reading said at least one RFID transponder in each model organism over a period of time; capturing a sequence of images of each model organism over said period of time; and calculating at least one spatiotemporal model of each model organism based on time synchronization of said RFID tracked position of said model organism with said sequence of images.

公开(公告)号：US09970891B2

公开(公告)日：2018-05-15

申请号：US15033911

申请日：2014-11-04

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Nirit Dudovich ,  Oren Raz ,  Boaz Nadler ,  Dan Oron

IPC: G06K9/00 ,  G01N23/205 ,  G03H1/08 ,  G03H1/12 ,  G02B21/00 ,  G02B21/36 ,  G06T7/30 ,  G01N23/20 ,  G03H5/00 ,  G03H1/04

CPC classification number: G01N23/2055 ,  G01N23/20 ,  G02B21/0056 ,  G02B21/367 ,  G03H1/0443 ,  G03H1/0866 ,  G03H1/12 ,  G03H5/00 ,  G03H2001/0447 ,  G03H2001/045 ,  G03H2001/0454 ,  G03H2222/42 ,  G06T7/30

Abstract: A method and system for use in reconstruction and retrieval of phase information associated with a two-dimensional diffractive response are presented. The method comprising: providing (75) input data indicative of one or more diffractive patterns corresponding to diffractive responses from one or more objects (50). Dividing (130) said input data into a plurality of one-dimensional slices and determining (140) one-dimensional phase data for at least some of said one-dimensional slices. Tailoring (150) the reconstructed phase data of said one-dimensional slices to form a two-dimensional phase solution. The two-dimensional phase solution is defined by phase shifts of said reconstructed one-dimensional phase data of said one-dimensional slices. The two-dimensional phase solution thus enables obtaining two-dimensional reconstructed phase data suitable for reconstruction of image data (250).

公开(公告)号：US20180118826A1

公开(公告)日：2018-05-03

申请号：US15821570

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K31/404 ,  A61K39/395 ,  A61K38/20 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20180105592A1

公开(公告)日：2018-04-19

申请号：US15821603

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K31/404 ,  A61K39/395 ,  A61K38/20 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20180064748A1

公开(公告)日：2018-03-08

申请号：US15561990

申请日：2016-03-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran HORNSTEIN ,  Irit REICHENSTEIN ,  Alon CHEN

IPC: A61K31/7105 ,  C12N15/113

CPC classification number: A61K31/7105 ,  A61K45/06 ,  A61P25/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141

Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.

公开(公告)号：US20180057533A1

公开(公告)日：2018-03-01

申请号：US15796811

申请日：2017-10-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Moshe OREN ,  Varda ROTTER ,  Perry TAL

IPC: C07K7/06 ,  C07K14/47 ,  C07K14/00 ,  C07K7/08 ,  A61K38/16 ,  A61K38/08 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/08 ,  A61K38/16 ,  C07K7/08 ,  C07K14/00 ,  C07K14/4746

Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.

公开(公告)号：US09901593B2

公开(公告)日：2018-02-27

申请号：US14856697

申请日：2015-09-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Alon Chen ,  Eran Hornstein ,  Orna Issler ,  Sharon Haramati ,  Naama Volk

IPC: C12N15/11 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/113 ,  C12Q1/68 ,  A61K48/00

CPC classification number: A61K31/7105 ,  A61K31/713 ,  A61K48/0058 ,  C12N15/113 ,  C12N2310/141 ,  C12Q1/6883 ,  C12Q2600/178

Abstract: microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided.

公开(公告)号：US09901299B2

公开(公告)日：2018-02-27

申请号：US15102588

申请日：2014-12-09

Applicant: Yeda Research and Development Co. Ltd. ,  Mor Research Applications Ltd.

Inventor： Lior Haviv ,  Noam Sobel ,  Amiram Catz ,  Itzhak Glass ,  Anton Plotkin ,  Aharon Weissbrod ,  Sagit Shushan

IPC: A61N1/00 ,  A61B5/00 ,  A61B5/087 ,  A61B5/11 ,  A61N1/36 ,  A61B5/0492 ,  A61B5/0488 ,  A61B5/08 ,  G06F3/01

CPC classification number: A61B5/4836 ,  A61B5/0488 ,  A61B5/0492 ,  A61B5/0806 ,  A61B5/0816 ,  A61B5/0823 ,  A61B5/087 ,  A61B5/1103 ,  A61B5/7282 ,  A61B5/7475 ,  A61N1/36003 ,  A61N1/3601 ,  A61N1/36014 ,  A61N1/36017 ,  G06F3/012

Abstract: A system for assisted coughing includes a first sensor for measuring a parameter which can indicate a closed glottis and producing a first signal, a processor for receiving the first signal, determining a state indicating the closed glottis and generating an instruction for a Functional Electric Stimulation (FES) controller based, at least in part, on the determining, and a FES controller for generating an electric stimulation signal.